Whether the determination of the CDA mRNA levels and/or methylation status could be useful for predicting the clinical responses of MDS patients should be further investigated using frozen and matched tumor samples obtained at optimized periods during 5AC treatment. This evidence concerns the gene CDA and myelodysplastic syndrome.